A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation

JRCT ID: jRCT2061230057

Registered date:12/09/2023

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Advanced/metastatic NSCLC with Exon 20 insertions and Uncommon/Single or Compound EGFR Mutations
• Date of first enrollment: 01/11/2023
• Target sample size: 60
• Countries of recruitment: United States,Japan,Australia,Japan,Canada,Japan,France,Japan,Germany,Japan,Hong Kong,Japan,Italy,Japan,Korea,Japan,Spain,Japan,Turkey,Japan,United Kingdom,Japan
• Study type: Interventional
• Intervention(s): CLN-081/TAS6417 is administered orally at a dose of 100 mg twice daily

Outcome(s)

• Primary Outcome: ORR, defined as the proportion of patients experiencing a best overall confirmed response of CR or PR, per RECIST 1.1.

Key inclusion & exclusion criteria

• Age minimum: >= 18age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

1. Provide written informed consent
2. Is >=18 years of age (or meets the country's regulatory definition of legal adult age, whichever is greater)
3. Has pathologically confirmed, locally advanced or metastatic NSCLC meeting all the following criteria:
a. Cohort A patients:
i. Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).
ii. Progressed on or after systemic therapy with an agent targeting ex20ins, either alone or in combination with standard platinum-based chemotherapy for the treatment of advanced disease. Patients who discontinued previous treatment due to unacceptable toxicity are eligible.
iii. Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.
b. Cohort B patients:
i. Documented EGFR ex20ins mutation status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).
ii. Not received prior systemic therapy for locally advanced or metastatic disease. Prior adjuvant/neoadjuvant treatment for early-stage disease must have been completed > 6 months prior to the first dose of study treatment.
iii. Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.
c. Cohort C patients:
i. Documented ex20ins or other non-ex20ins uncommon single or compound EGFRmt status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US).
ii. Presence of brain metastasis(es), which may be measurable or nonmeasurable by RANO-BM criteria, characterized as one of the following:
a. Newly diagnosed and/or progressive brain metastasis (es) not subjected to CNS-directed therapy, OR
b. Leptomeningeal disease (LMD) confirmed by a positive cerebrospinal fluid cytology, or unequivocal radiographic and/or clinical determination.
d. Cohort D patients:
i. Documented other non-ex20ins uncommon single or compound EGFRmt status, as determined by local testing performed at a CLIA certified (US) or locally certified laboratory (outside the US). A list of eligible mutations will be provided in a separate manual.
ii.Patients with brain metastasis must be neurologically stable. Patients must have received CNS-directed therapy and have no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (MRI or CT scan) during the screening period, and they must be on a stable or decreasing dose of corticosteroids and/or anti-convulsant medications for at least 2 weeks prior to the first dose of study treatment. Patients with history of uncontrolled seizures or leptomeningeal disease are not eligible.
4. Measurable disease per RECIST 1.1.
5. Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers (details provided in a laboratory manual). Patients with insufficient tissue may be eligible following discussion with the sponsor.
6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1.

Exclude criteria

1. Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged to be scientifically or medically incompatible with this study.
2. Has received any of the following within the specific time frame specified:
a. Zipalertinib (TAS6417/CLN081) at any time.
b. Thoracic radiotherapy <=28 days or palliative radiation <=14 days prior to the first dose of study treatment.
c. Anticancer immunotherapy <=28 days prior to the first dose of study treatment.
d. Major surgery (excluding placement of vascular access) <=28 days prior to the first dose of study treatment.
3. Have any unresolved toxicity of Grade >=2 from previous anticancer treatment, except for Grade 2 alopecia or skin pigmentation. Patients with other chronic but stable Grade 2 toxicities may be allowed to enroll after agreement between the investigator and Sponsor.
4. Past medical history of interstitial lung disease, treatment-related pneumonitis (any grade), or evidence of clinically active interstitial lung disease.
5. Impaired cardiac function or clinically significant cardiac disease, including any of the following:
a. History of congestive heart failure (CHF) Class III/IV according to the New York Heart Association (NYHA) Functional Classification (Appendix A).
b. Serious cardiac arrhythmias requiring treatment.
c. Resting corrected QT interval (QTc) >470 msec using Fridericia's formula (QTcF).
6. Is unable to swallow tablets/capsules or has any disease or condition that may significantly affect gastrointestinal absorption of zipalertinib (e.g., inflammatory bowel disease, malabsorption syndrome, or prior gastric/bowel resection).
7. History of another primary malignancy <=2 years prior to the date of the first dose of study treatment unless at least one of the following criteria are met:
a. Adequately treated basal or squamous cell carcinoma of the skin.
b. Cancer of the breast or cervix in situ.
c. Patients with previously treated malignancy if all treatment for that malignancy was completed at least 2 years prior to randomization and no evidence of disease.
d. Patients with concurrent malignancy clinically stable and not requiring tumor-directed treatment.
8. Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is not controlled with treatment.
9. History of COVID-19 infection within 4 weeks prior to enrollment and/or has persistent clinically significant pulmonary symptoms related to prior COVID-19 infection.
10. Active bleeding disorders.
11. Known hypersensitivity to the ingredients in zipalertinib or any drugs similar in structure or class.
12. Is pregnant or lactating.

Related Information

• Primary Sponsor: Dempke Wolfram
• Secondary ID(s): NCT05967689